23 Dec 2020 --- US-based synthetic biotechnology company Amyris has closed a strategic transaction with DSM Nutritional Products. Under the terms of the agreement, Amyris is licensing DSM rights to assume the supply of farnesene – a bio-based compound – to Givaudan for the production and sale of a single specialty ingredient.